Dipeptidyl Peptidase-4 Inhibitors and Bone Fractures A meta-analysis of randomized clinical trials
نویسندگان
چکیده
RESULTSdTwenty-eight trials enrolling 11,880 and 9,175 patients for DPP-4 inhibitors and comparators, respectively, were included, reporting 63 fractures. DPP-4 inhibitors, compared with placebo or other treatments, were associated with a reduced risk of fractures (Mantel– Haenszel odds ratio [MH-OR] 0.60, 95% CI 0.37–0.99, P = 0.045), even after the exclusion of comparisons with thiazolidinediones or sulfonylureas (MH-OR 0.56, 0.33–0.93, P = 0.026).
منابع مشابه
Dipeptidyl Peptidase-4 Inhibitors and Bone Fractures
OBJECTIVE Thiazolidinediones and insulin are associated with a higher risk of fractures in type 2 diabetic patients. Incretin hormones increase bone density in experimental models, but the effect of dipeptidyl peptidase-4 (DPP-4) inhibitors on bone fractures has not been reported so far. RESEARCH DESIGN AND METHODS A meta-analysis was performed including all randomized clinical trials with a ...
متن کاملDipeptidyl peptidase-4 inhibitors and fracture risk: an updated meta-analysis of randomized clinical trials
Data on the effects of dipeptidyl peptidase-4 (DPP-4) inhibitors on fracture risk are conflicting. Here, we performed a systematic review and meta-analysis of randomized controlled trials (RCTs) assessing the effects of DPP-4 inhibitors. Electronic databases were searched for relevant published articles, and unpublished studies presented at ClinicalTrials.gov were searched for relevant clinical...
متن کاملDipeptidyl peptidase‐4 inhibitors and prevention of bone fractures: Effects beyond glyemic control
Dipeptidyl peptidase-4 (DPP-4) inhibitors improve glycemic control in patients with type 2 diabetes by preventing degradation of two incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). GLP-1 and GIP are secreted from the intestine on ingestion of various nutrients, and enhance insulin secretion from pancreatic b-cells glucose-dependently. B...
متن کاملComment on: Monami et al. Dipeptidyl Peptidase-4 Inhibitors and Bone Fractures: A Meta-analysis of Randomized Clinical Trials. Diabetes Care 2011;34:2474–2476
I recently read an interesting article in Diabetes Care (1) that showed that treatment with dipeptidyl peptidase-4 (DPP-4) inhibitors could be associated with a reduced risk of bone fractures in type 2 diabetic patients. As the authors pointed out, since experimental data in animal models suggested that incretins such as glucagon-like peptide-1 (GLP-1) and gastric intestinal polypeptide (GIP) s...
متن کاملDipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials.
AIMS Preliminary data from randomized trials with metabolic outcomes have shown that treatment with dipeptidyl peptidase-4 inhibitors (DPP4i) could be associated with a reduced incidence of major cardiovascular events (MACE). The present meta-analysis is aimed at verifying this protective effect, collecting all available data from randomized trials. METHODS A comprehensive search for publishe...
متن کامل